期刊文献+

P(HPMA-APMA)-ATRA的合成及其对HL-60细胞诱导分化能力的评估

Preparation of P(HPMA)-APMA-ATRA and Assessment of Its Induction of HL-60 Cell Differentiation
原文传递
导出
摘要 以N-(2-羟丙基)甲基丙烯酰胺(HPMA),N-(3-氨基丙基)甲基丙烯酰胺(APMA)和金反式维甲酸(ATRA)为原料,采用自由基溶液聚合法设计合成P(HPMA-APMA).ATRA,并用核磁共振氢谱对该化合物进行结构表征.相比于单体ATRA,聚合物的水溶性显著增加,同时可通过胞吞作用进入细胞.3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法评估聚合物和单体ATRA对人早幼粒白血病细胞HL-60生长的抑制作用,流式细胞术检测两者对HL-60细胞周期分布及细胞表面抗原CDllb表达的影响,进一步结合氯化硝基四氮唑蓝(NBT)还原法评估聚合物诱导HL-60细胞分化的能力.结果显示,聚合物比单体ATRA具有更强的细胞生长抑制活性,其IC_50值分别为1.03和4.09μmol/L;聚合物还具有更高的G_0/G_1期细胞阻滞效应,1.2μmol/L时,聚合物比单体ATRA的G_0/G_1期细胞率高出17.7%;同样,0.4μmol/L聚合物与2.4μmaol/L单体ATRA诱导HL-60的NBT还原能力相当,0.8μmaol/L聚合物与2.4μmol/L单体ATRA诱导HL-60细胞表面抗原CDllb表达相当,表明聚合物比单体ATRA具有更强的诱导HL-60细胞向粒细胞分化的能力,其药效增强3~4倍. P(HPMA-APMA)-ATRA was synthesized by free-radical solution polymerization with N-(2-hydroxypropyl methacrylamide) (HPMA), N-(3-aminopropyl) methacrylamide (APMA) and all-trans retinoic acid (ATRA) as raw materials. The structure of the polymer was confirmed by 1H NMR. Compared with the monomeric ATRA, the water-solubility of the polymer increased significantly and could enter the cells through endocytosis. The inhibition of polymerized and monomeric ATRA on HL-60 cell growth was assessed by MTT(3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide). Then flow cytometry was used to detect the effects of the two compounds on cell cycle distribution and expression of cell surface antigen CDllb in HL-60 cell. Finally, a further experiment with NBT (nitroblue tetrazolium) was conducted to analyze the cell differentiation of HL-60 induced by the two compounds. The P-ATRA showed a stronger suppressive ability on cell growth than monomeric ATRA, the IC50 was 1.03 and 4.09 μmol L-1, respectively. The P-ATRA had a higher G0/G1 phase cell block effect. At the concentration of 1.2 μmol L-1, G0/G1 phase cell rate induced by P-ATRA was 17.7% higher than that of monomeric ATRA. The NBT reduction ability of HL-60 induced by 0.4 μmol L-1 P-ATRA was similar with that of 2.4 μmol L-: ATRA, the expression of cell surface antigen CD1 lb in HL-60 cell induced by 0.8 μmol L-1 P-ATRA was similar with that of 2.4 μmol L-1 ATRA, and the results indicated that the differentiation of HL-60 cell induced by P-ATRA increased 3-4 folds compared to that of ATRA.
出处 《中国科学:生命科学》 CSCD 北大核心 2014年第5期471-480,共10页 Scientia Sinica(Vitae)
基金 国家自然科学基金(批准号:30960464) 西北师范大学“知识与科技创新工程”项目(批准号:NWNU-KJCXGC-03-65)资助
关键词 全反式维甲酸 P(HPMA)-APMA P(HPMA)-APMA-ATRA 细胞分化 all-trans retinoic acid, P(HPMA-APMA), P(HPMA-APMA)-ATRA, cell differentiation
  • 相关文献

参考文献29

  • 1Warrell J R, Wang Z Y, Degos L. Acute promyelocytic leukemia. New Engl J Med, 1993, 329:177-189.
  • 2Freemantle S J, Spinella M J, Dmitrovsky E, et al. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene, 2003, 22:7305-7315.
  • 3Okuno M, Kojima S, Matsushima-Nishiwaki R, et al. Retinoids in cancer chemoprevention. Curr Cancer Drug Targets, 2004, 4:285-298.
  • 4Sun S Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol, 2002, 41:41-55.
  • 5Ross S A, McCaffery P J, Drager U C, et al. Retinoids in embryonal development. Physiol Rev, 2000, 80:1021-1054.
  • 6Wan'ell R P Jr, Frankel S R, Miller W H Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans- retinoic acid). New Engl J Med, 1991, 324:1385-1393.
  • 7Patatanian E, Thompson D F. Retinoic acid syndrome: a review. J Clin Pharm Ther, 2008, 33:331-338.
  • 8Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood, 1995, 85:2643-2653.
  • 9Leo M A, Lasker J M, Raucy J L, et al. Metabolism of retinol and retinoic acid by human liver cytochrome P4501IC8. Arch Biochem Biophys, 1989, 269:305-312.
  • 10Muindi J, Frankel S R, Miller J R, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood, 1992, 79: 299-303.

二级参考文献28

  • 1Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate[ J ]. Eur J Pharm Biopharm, 2008, 70 :726 -734.
  • 2Liu B, Yang M, Li X, et al. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer[J]. J Pharm Sci, 2007, 97(8) :3170 -3181.
  • 3Chen S, Zhang XZ, Cheng SX, et al. Funetionalized amphiphilic byperbranched polymers for targeted drug delivery[J]. Biomacromolecules, 2008, 9:2578 - 2585.
  • 4Ademuyiwa FO, Miller KD. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer[ J ]. Clin Breast Cancer, 2008, 8 ( Suppl 4) : 151 - 156.
  • 5Leamon CP, Reddy JA. Folate-targeted chemotherapy [ J ]. Adv Drug Deliv Rev, 2004, 56 : 1127 - 1141.
  • 6Wong HL, Bendayan R, Rauth AM, et al. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymerlipid hybrid nanoparticle syslem[J]. J Pharmacol Exp Ther, 2006, 317:1372 - 1351.
  • 7Green MR, Manikhas GM, Orlov S, et al. Abraxane(R), a novel cremophor(R) -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer[ J]. Annals of Oncology, 2006, 17 ( 8 ) : 1263 - 1268.
  • 8Limentanil SA,Anthony A, Heafner M, et al. A phase Ⅰ trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary ariaplastic astrocytoma or glioblastoma multiforme[ J]. J Neurooncol, 2005,72(3) : 241 -244.
  • 9Matsumura Y. Polymeric micellar delivery systems in oncology [J]. Jpn J Clin Oncol, 2008, 38:793 -802.
  • 10Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics[ J]. Adv Drug Deliv Rev, 2008, 60 : 1615 - 1626.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部